中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (11): 943-950.doi: 10.35541/cjd.20210547
中华医学会皮肤性病学分会儿童学组 中国医师协会皮肤科医师分会儿童皮肤病学组 中华医学会儿科学分会皮肤性病学组 中国康复医学会皮肤病康复专业委员会儿童皮肤病康复学组
收稿日期:
2021-07-29
修回日期:
2021-09-13
发布日期:
2021-11-01
通讯作者:
马琳;王华
E-mail:bch_maleen@aliyun.com; huawang@hospital.cqmu.edu.cn
Group on Children, Chinese Society of Dermatology; Group on Pediatric Dermatology, China Dermatologist Association; Dermatology and Venereology Group, Chinese Pediatric Society, Chinese Medical Association; Pediatric Dermatology Rehabilitation Group, Chinese Association of Rehabilitation Dermatology
Received:
2021-07-29
Revised:
2021-09-13
Published:
2021-11-01
Contact:
Ma Lin; Wang Hua
E-mail:bch_maleen@aliyun.com; huawang@hospital.cqmu.edu.cn
摘要: 【摘要】 对于中重度儿童银屑病,若外用药治疗无法控制病情,临床则需要考虑系统治疗。儿童属于生物制剂应用的特殊人群,应用的剂量、疗效及安全性与成人不尽相同。为此,我国儿童银屑病诊疗领域部分专家依据国内外指南及共识、相关文献及临床经验,经过深入讨论,制定本共识。从生物制剂的应用原则、应用方法、疗效及安全性、疗程及停药时机、用药前筛查及用药过程中监测等方面提供指导性意见,希望为我国中重度儿童银屑病患者生物制剂的应用提供参考依据。
中华医学会皮肤性病学分会儿童学组 中国医师协会皮肤科医师分会儿童皮肤病学组 中华医学会儿科学分会皮肤性病学组 中国康复医学会皮肤病康复专业委员会儿童皮肤病康复学组. 中国儿童银屑病生物治疗专家共识(2021)[J]. 中华皮肤科杂志, 2021,54(11):943-950. doi:10.35541/cjd.20210547
Group on Children, Chinese Society of Dermatology, Group on Pediatric Dermatology, China Dermatologist Association, Dermatology and Venereology Group, Chinese Pediatric Society, Chinese Medical Association, Pediatric Dermatology Rehabilitation Group, Chinese Association of Rehabilitation Dermatology. Treatment of pediatric psoriasis with biological agents: a Chinese expert consensus statement (2021) [J]. Chinese Journal of Dermatology, 2021, 54(11): 943-950.doi:10.35541/cjd.20210547
[1] | Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review[J]. Int J Mol Sci, 2020,21(5):1690. doi: 10. 3390/ijms21051690. |
[2] | Fotiadou C, Lazaridou E. Psoriasis and uveitis: links and risks[J]. Psoriasis (Auckl), 2019,9:91⁃96. doi: 10.2147/PTT.S179182. |
[3] | Alsenaid A, Ezmerli M, Srour J, et al. Biologics and small molecules in patients with scalp psoriasis: a systematic review[J]. J Dermatolog Treat, 2020:1⁃10. doi: 10.1080/09546634.2020. 1770167. |
[4] | Misiak⁃Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments[J]. Am J Clin Dermatol, 2020,21(3):355⁃370. doi: 10.1007/s40257⁃020⁃00503⁃5. |
[5] | Smith MP, Ly K, Thibodeaux Q, et al. Acrodermatitis continua of Hallopeau: clinical perspectives[J]. Psoriasis (Auckl), 2019,9:65⁃72. doi: 10.2147/PTT.S180608. |
[6] | Bardazzi F, Starace M, Bruni F, et al. Nail psoriasis: an updated review and expert opinion on available treatments, including biologics[J]. Acta Derm Venereol, 2019,99(6):516⁃523. doi: 10.2340/00015555⁃3098. |
[7] | Micali G, Verzì AE, Giuffrida G, et al. Inverse psoriasis: from diagnosis to current treatment options[J]. Clin Cosmet Investig Dermatol, 2019,12:953⁃959. doi: 10.2147/CCID.S189000. |
[8] | Ollech A, Zvulunov A, Pavlovsky L, et al. Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center[J]. J Dermatolog Treat, 2019,30(2):152⁃155. doi: 10.1080/09546634.2018.1476655. |
[9] | Bronckers I, Seyger M, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis[J]. JAMA Dermatol, 2017,153(11):1147⁃1157. doi: 10.1001/jamadermatol.2017.3029. |
[10] | Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis[J]. N Engl J Med, 2008,358(3):241⁃251. doi: 10.1056/NEJMoa066886. |
[11] | Paller AS, Siegfried EC, Pariser DM, et al. Long⁃term safety and efficacy of etanercept in children and adolescents with plaque psoriasis[J]. J Am Acad Dermatol, 2016,74(2):280⁃287. doi: 10.1016/j.jaad.2015.09.056. |
[12] | Foeldvari I, Constantin T, Vojinović J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis⁃related arthritis, or psoriatic arthritis: 6⁃year efficacy and safety data from an open⁃label trial[J]. Arthritis Res Ther, 2019,21(1):125. doi: 10.1186/s13075⁃019⁃1916⁃9. |
[13] | 鲁珊, 周薇, 张倩, 等. 幼年银屑病关节炎[J]. 中国当代儿科杂志, 2007,9(4):339⁃342. doi: 10.3969/j.issn.1008⁃8830.2007. 04.014. |
[14] | Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin⁃36 receptor antagonist (DITRA) in children and adolescents[J]. Pediatr Rheumatol Online J, 2019,17(1):37. doi: 10.1186/s12969⁃019⁃0338⁃1. |
[15] | Papoutsaki M, Costanzo A, Mazzotta A, et al. Etanercept for the treatment of severe childhood psoriasis[J]. Br J Dermatol, 2006,154(1):181⁃183. doi: 10.1111/j.1365⁃2133.2005.06982.x. |
[16] | Fialová J, Vojáčková N, Vaňousová D, et al. Juvenile generalized pustular psoriasis treated with etanercept[J]. Dermatol Ther, 2014,27(2):105⁃108. doi: 10.1111/dth.12065. |
[17] | Armaroli G, Klein A, Ganser G, et al. Long⁃term safety and effectiveness of etanercept in JIA: an 18⁃year experience from the BiKeR registry[J]. Arthritis Res Ther, 2020,22(1):258. doi: 10.1186/s13075⁃020⁃02326⁃5. |
[18] | Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial[J]. Lancet, 2017,390(10089):40⁃49. doi: 10.1016/S0140⁃6736(17)31189⁃3. |
[19] | Thaçi D, Papp K, Marcoux D, et al. Sustained long⁃term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double⁃blind, phase III study[J]. Br J Dermatol, 2019,181(6):1177⁃1189. doi: 10.1111/bjd.18029. |
[20] | Horneff G, Seyger M, Arikan D, et al. Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis⁃related arthritis, psoriasis, and crohn′s disease[J]. J Pediatr, 2018,201:166⁃175. doi: 10.1016/j.jpeds.2018.05.042. |
[21] | Craiglow BG, Boyden LM, Hu R, et al. CARD14⁃associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris[J]. J Am Acad Dermatol, 2018,79(3):487⁃494. doi: 10.1016/j.jaad.2018.02.034. |
[22] | Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate⁃to⁃severe plaque psoriasis: results of the randomized phase 3 CADMUS study[J]. J Am Acad Dermatol, 2015,73(4):594⁃603. doi: 10.1016/j.jaad.2015.07.002. |
[23] | Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open⁃label CADMUS Jr study[J]. Br J Dermatol, 2020,183(4):664⁃672. doi: 10.1111/bjd.19018. |
[24] | Magnolo N, Kingo K, Laquer V, et al. Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 52⁃week results from a randomized trial[C/OL]//American Academy of Dermatology Virtual Meeting Experience(AAD VMX), online, 2021[2021⁃10⁃19]. https://eposters.aad.org/abstracts/26860. |
[25] | Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52⁃week results from a Phase 3 double⁃blind randomized, controlled trial[J]. J Eur Acad Dermatol Venereol, 2021,35(4):938⁃947. doi: 10.1111/jdv.17002. |
[26] | 谢辉, 牛美丽, 王新慧, 等. 司库奇尤单抗治疗儿童银屑病六例疗效评价[J]. 中国麻风皮肤病杂志, 2021,37(3):157⁃159,162. doi: 10.12144/zgmfskin202103157. |
[27] | 孙勇虎, 张福仁. 白介素17A拮抗剂治疗儿童银屑病一例并文献复习[J]. 中国麻风皮肤病杂志, 2021,37(1):30⁃31,36. doi: 10.12144/zgmfskin202101030. |
[28] | Paller AS, Seyger M, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double⁃blind, placebo⁃controlled study in paediatric patients with moderate⁃to⁃severe plaque psoriasis (IXORA⁃PEDS)[J]. Br J Dermatol, 2020,183(2):231⁃241. doi: 10.1111/bjd.19147. |
[29] | Ferrara G, Losi M, D′Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study[J]. Lancet, 2006,367(9519):1328⁃1334. doi: 10.1016/S0140⁃6736(06)68579⁃6. |
[30] | Bagel J. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis[J]. J Drugs Dermatol, 2011,10(4):366⁃371. |
[31] | Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks[J]. Br J Dermatol, 2011,164(6):1383⁃1386. doi: 10.1111/j.1365⁃2133. 2011.10358.x. |
[32] | Wolf P, Weger W, Legat FJ, et al. Treatment with 311⁃nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab⁃treated patients: a randomized intraindividual trial[J]. Br J Dermatol, 2012,166(1):147⁃153. doi: 10.1111/j.1365⁃2133.2011.10616.x. |
[33] | Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept[J]. J Dermatolog Treat, 2012,23(4):261⁃267. doi: 10.3109/09546634. 2011.607795. |
[34] | Park KK, Wu JJ, Koo J. A randomized, ′head⁃to⁃head′ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB⁃UVB) phototherapy in obese psoriasis patients[J]. J Eur Acad Dermatol Venereol, 2013,27(7):899⁃906. doi: 10.1111/j.1468⁃3083.2012.04611.x. |
[35] | Cather JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis[J]. Am J Clin Dermatol, 2014,15(6):467⁃478. doi: 10.1007/s40257⁃014⁃0097⁃1. |
[36] | Heinecke GM, Luber AJ, Levitt JO, et al. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center[J]. J Drugs Dermatol, 2013,12(10):1098⁃1102. |
[37] | Bissonnette R, Maari C, Barber K, et al. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab[J]. J Eur Acad Dermatol Venereol, 2015,29(8):1576⁃1581. doi: 10.1111/jdv.12943. |
[38] | Downs AM. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab[J]. Br J Dermatol, 2010,163(2):433⁃434. doi: 10.1111/j.1365⁃2133.2010. 09832.x. |
[39] | Hu Y, Chen Z, Gong Y, et al. A review of switching biologic agents in the treatment of moderate⁃to⁃severe plaque psoriasis[J]. Clin Drug Investig, 2018,38(3):191⁃199. doi: 10.1007/s40261⁃017⁃0603⁃3. |
[40] | Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double⁃blind, phase III NAVIGATE trial[J]. Br J Dermatol, 2018,178(1):114⁃123. doi: 10.1111/bjd.15750. |
[41] | Sator P, Richter L, Saxinger W, et al. Adalimumab in the treatment of moderate⁃to⁃severe chronic plaque psoriasis in patients switching from other biologics[J]. J Eur Acad Dermatol Venereol, 2015,29(9):1742⁃1749. doi: 10.1111/jdv.12981. |
[42] | Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics[J]. J Am Acad Dermatol, 2020,82(1):213⁃221. doi: 10.1016/j.jaad.2019.05.056. |
[43] | Smith CH, Yiu Z, Bale T, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update[J]. Br J Dermatol, 2020,183(4):628⁃637. doi: 10.1111/bjd. 19039. |
[44] | Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics[J]. J Am Acad Dermatol, 2019,80(4):1029⁃1072. doi: 10.1016/j.jaad.2018.11.057. |
[45] | Huber F, Ehrensperger B, Hatz C, et al. Safety of live vaccines on immunosuppressive or immunomodulatory therapy⁃a retrospective study in three Swiss Travel Clinics[J]. J Travel Med, 2018,25(1). doi: 10.1093/jtm/tax082. |
[46] | Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature[J]. J Am Acad Dermatol, 2017,77(1):88⁃97. doi: 10.1016/j.jaad.2017.01.037. |
[1] | 张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767. |
[2] | 李妍, 李明, 徐薇, 李邻峰. [本文开放获取] 丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 0(4): 20210246-e20210246. |
[3] | 李赛, 薛华忠, 张树文, 蒋娟, 齐淑贞, 赵园园, 张津萍, 沙仲, 乐文静, 王碧伟, 赵诗轩, 朱小凤, 苏晓红. 多西环素-莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210631-e20210631. |
[4] | 王玥, 严煜林. 寻常型银屑病患者171例阿维A治疗相关不良反应及停药原因分析[J]. 中华皮肤科杂志, 2022, 0(2): 20200867-e20200867. |
[5] | 焦晓燕, 尹光文, 阴亚坤, 李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 0(2): 20210384-e20210384. |
[6] | 王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115. |
[7] | 何瑞, 张斌, 李丽, 尉莉, 张楠, 于彤, 阴捷, 徐子刚, 马琳. 外用西罗莫司治疗儿童浅表脉管畸形19例的临床疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(2): 129-134. |
[8] | 欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184. |
[9] | 包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156. |
[10] | 郭静 杨景煜 丁黎 刘明明 侯晶梅 蒲小霞 孙嘉昱 李向花. 长脉宽1 064 nm Nd:YAG激光联合含滇山茶和三七等提取物的外用乳剂治疗黄褐斑的疗效[J]. 中华皮肤科杂志, 2022, 55(1): 61-64. |
[11] | 赵莹 王娟娟 季江 苏文星 魏钰倩 冷红 丁瑜洁 施辛. 白细胞介素17A介导银屑病及心血管合并症的研究进展[J]. 中华皮肤科杂志, 2022, 55(1): 76-79. |
[12] | 高蓉 张兰 李政霄. 生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展[J]. 中华皮肤科杂志, 2022, 55(1): 72-75. |
[13] | 孔雪 史冬梅 刘维达. 抗真菌药在特殊人群的应用[J]. 中华皮肤科杂志, 2022, 55(1): 80-83. |
[14] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识(2022)[J]. 中华皮肤科杂志, 2022, 55(1): 1-11. |
[15] | 陆佳维, 鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210420-e20210420. |
|